HIV mutation literature information.


  HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries.
 PMID: 21390473       2010       Acta dermatovenerologica Alpina, Pannonica, et Adriatica
Abstract: Ninety percent of sequences with genotypic resistance harbored M184V, M41L, K103N, D67N, and/or T215Y.


  Allele-specific real-time PCR testing for minor HIV-1 drug resistance mutations: assay preparation and application to reveal dynamic of mutations in vivo.
 PMID: 22166519       2010       Chinese medical journal
Abstract: METHODS: We developed the allele-specific PCR assay, using the most common drug resistance mutations in Chinese AIDS patients, K103N, M184V/I, T215F/Y as a model system.
Abstract: RESULTS: The sensitivities of ASPCR assay were 0.04% for K103N, 0.30% for M184I, 0.40% for M184V, 0.03% for T215F and 0.02% for T215Y.
Abstract: The mutation of T215Y emerged 1 to 1.5 years after starting treatment and then increased rapidly.


  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
 PMID: 19143530       2009       Clinical infectious diseases
Abstract: HIV-1-associated thymidine analogue mutations (M41L, D67N, K70R, L210W, and T215Y/F) were not observed, with the exception of K70R, which was present together with K65R and Q151M in a strain from 1 patient.
Result: HIV-1-associated thymidine analogue mutations (M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E) were not found, with the exception of K70R, which was present in a strain from 1 patient (in conjunction with K65R


  HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure.
 PMID: 19203393       2009       Retrovirology
Introduction: M154I, V165I and M185L) positively associated with specific RT mutations (F227L and T215Y) in samples from treated individuals.


  Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations.
 PMID: 19223637       2009       Antimicrobial agents and chemotherapy
Abstract: Human immunodeficiency virus type 1 containing the reverse transcriptase mutation M184V or K65R or mutations M41L, M184V, and T215Y did not accumulate additional resistance mutations in the reverse transcriptase when increasing amounts of apricitabine drug pressure were applied.


  Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.
 PMID: 19277127       2009       PloS one
Discussion: have shown that certain NRTI mutations, including T215Y, can increase the fitness of K101E+G190S variants.


  Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.
 PMID: 19358668       2009       The Journal of infectious diseases
Result: In contrast to HIV-1NL4-3, HIV-2ROD mutants that harbored M41L, T215Y, or both substitutions showed no detectable resistance to AZT in the single-cycle assay (<2-fold increase in EC50 relative to WT HIV-2ROD) (figure A3 in appendix A, which appears only in the electronic version of the Journal).
Result: We constructed HIV-1NL4 3 and HIV-2ROD variants encoding 2 pivotal replacements in the TAM series (M41L and T215Y) and compared their sensitivities to AZT.
Discussion: Second, 2 key replacements in the TAM pathway (M41L and T215Y) have no effect on AZT susceptibility in HIV-2 in culture (figure A3 in appendix A, which appears only in the electronic version of the Journal).


  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
 PMID: 19417582       2009       AIDS (London, England)
Method: NRTI mutations included K65R and K70E (associated with TDF resistance), thymidine analog mutations (TAMs) M41L, D67N, K70R, L210W, T215Y, T215F, K219Q, and K219E, and multinucleoside mutations, including the 69 insertion complex and the 151 complex.
Result: The most frequent TAMs were T215 F/Y (73%), D67N (53%), K70R (36%), M41L (36%), K219 Q/E (23%), and L210W (23%).


  Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients.
 PMID: 19428602       2009       Antiviral research
Introduction: The excision mechanism is associated with mutations at the polymerase domain, including M41L, D67N, K70R, L210W, T215F/Y and K219E/Q (excision-containing mutations, EEMs, also known as thymidine analogue-associ
Discussion: The Type I EEMs (M41L, L210W, T215Y and occasionally the D67N mutation) appear twice as frequently as Type II EEMs (D67N, K70R, T215F and K219Q mutation) in subtype B, whereas Type II EEMs are mostly observed in non-B isolates.


  Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.
 PMID: 19433560       2009       Antimicrobial agents and chemotherapy
Abstract: Two (1.6%) unrelated patients harbored nucleoside reverse transcriptase inhibitor- and nonnucleoside reverse transcriptase inhibitor-resistant viruses (mutations: M41L, D67N, M184V, L210W, T215Y or T215F, and K103N).



Browser Board

 Co-occurred Entities




   Filtrator